Can Fite Biopharma Ltd (CANF) Short Interest Up 54.3% in December

Can Fite Biopharma Ltd (NYSEAMERICAN:CANF) was the recipient of a large increase in short interest in the month of December. As of December 29th, there was short interest totalling 45,202 shares, an increase of 54.3% from the December 15th total of 29,295 shares. Based on an average trading volume of 138,119 shares, the short-interest ratio is presently 0.3 days.

Shares of Can Fite Biopharma (NYSEAMERICAN:CANF) traded up $0.24 during trading on Wednesday, reaching $1.90. The company’s stock had a trading volume of 973,900 shares, compared to its average volume of 264,083. Can Fite Biopharma has a 52-week low of $1.24 and a 52-week high of $2.67. The firm has a market cap of $25.30, a P/E ratio of 6.24 and a beta of 1.37.

A number of analysts have weighed in on the company. Maxim Group set a $7.00 price target on Can Fite Biopharma and gave the stock a “buy” rating in a report on Monday, December 18th. HC Wainwright set a $6.00 price target on Can Fite Biopharma and gave the stock a “buy” rating in a report on Tuesday, October 31st.

COPYRIGHT VIOLATION NOTICE: “Can Fite Biopharma Ltd (CANF) Short Interest Up 54.3% in December” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/10/can-fite-biopharma-ltd-canf-short-interest-up-54-3-in-december.html.

Can Fite Biopharma Company Profile

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.

Receive News & Ratings for Can Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply